The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

Merck has licensed an early-stage cancer drug from a China-based biotech in an up to $3.3 billion deal, two months after a ...

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

Shares of Immutep (NASDAQ:IMMP) climbed 11% Thursday after the Australian company reported positive data from two clinical trials of its drug candidate eftilagimod alpha, or efti. Immutep (IMMP) said ...

today announces positive data from the investigator-initiated INSIGHT-003 Phase I trial evaluating eftilagimod alpha (efti) ...

Immutep (IMMP) announces the presentation of new data from EFTISARC-NEO, a Phase II investigator-initiated trial of eftilagimod alpha in ...

Thursday announced positive data from INSIGHT-003 Phase I trial, evaluating the addition of Eftilagimod alpha or ...

Immutep's American depositary receipts jumped after the company reported positive data from a trial evaluating its drug Efti in combination with Merck's therapy Keytruda for treating non-small cell ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Jemperli plus chemotherapy demonstrated superior overall survival compared to Keytruda in advanced NSCLC, with a median OS of ...

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September and, according to ...